GZ17-6.02 + capecitabine

GZ17-6.02 + capecitabine is an investigational combination therapy for cancer, pairing **GZ17-6.02** (a synthetic, orally administered, multi-component agent composed of isovanillin, harmine, and curcumin[1][5]) with capecitabine, an oral prodrug of 5-fluorouracil. **GZ17-6.02** acts via inhibition of transcriptional super-enhancers, activation of the DNA damage response (notably ATM kinase), AMPK activation, mTOR inhibition, pronounced induction of macroautophagy, and modulation of ER stress pathways (PERK activation, eIF2α phosphorylation)[1][3][4][5]. Capecitabine is a cytotoxic antimetabolite primarily used for several solid tumors. This combination is in clinical trials for patients with advanced solid malignancies including pancreatic and colorectal cancer. The developer for GZ17-6.02 is Genzada Pharmaceuticals[1][5].